TY - JOUR
T1 - The Alzheimer's Biomarker Consortium-Down Syndrome
T2 - Rationale and methodology
AU - the Alzheimer's Biomarker Consortium – Down Syndrome (ABC-DS)
AU - Handen, Benjamin L.
AU - Lott, Ira T.
AU - Christian, Bradley T.
AU - Schupf, Nicole
AU - OBryant, Sid
AU - Mapstone, Mark
AU - Fagan, Anne M.
AU - Lee, Joseph H.
AU - Tudorascu, Dana
AU - Wang, Mei Cheng
AU - Head, Elizabeth
AU - Klunk, William
AU - Ances, Beau M.
AU - Lai, Florence
AU - Zaman, Shahid
AU - Krinsky-McHale, Sharon
AU - Brickman, Adam M.
AU - Rosas, H. Diana
AU - Cohen, Annie
AU - Andrews, Howard
AU - Hartley, Sigan
AU - Silverman, Wayne
AU - Aizenstein, Howard J.
AU - Andrews, Howard F.
AU - Bell, Karen
AU - Birn, Rasmus M.
AU - Bulova, Peter
AU - Cheema, Amrita
AU - Chen, Kewei
AU - Clare, Isabel
AU - Clark, Lorraine
AU - Cohen, Ann D.
AU - Constantino, John N.
AU - Doran, Eric W.
AU - Feingold, Eleanor
AU - Foroud, Tatiana M.
AU - Hartley, Sigan L.
AU - Henson, Rachel
AU - Hom, Christy
AU - Honig, Lawrence
AU - Ikonomovic, Milos D.
AU - Johnson, Sterling C.
AU - Jordan, Courtney
AU - Kamboh, M. Ilyas
AU - Keator, David
AU - Kofler, Julia K.
AU - Kreisl, William Charles
AU - Krinsky-McHale, Sharon J.
AU - Lao, Patrick
AU - Silverman, Wayne P.
N1 - Publisher Copyright:
© 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association
PY - 2020
Y1 - 2020
N2 - Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.
AB - Introduction: Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments. Methods: We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression. Results: Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and statistical cores is provided. Discussion: This represents the largest U.S.-based, multi-site, biomarker initiative of AD in DS. Findings can inform other multidisciplinary networks studying AD in the general population.
KW - ABC-DS
KW - Alzheimer's disease
KW - Down syndrome
KW - dementia
UR - http://www.scopus.com/inward/record.url?scp=85108596995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108596995&partnerID=8YFLogxK
U2 - 10.1002/dad2.12065
DO - 10.1002/dad2.12065
M3 - Review article
C2 - 32775597
AN - SCOPUS:85108596995
SN - 2352-8729
VL - 12
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
IS - 1
M1 - e12065
ER -